NKTR $21.60

0.85 (3.8%)


NKTR Profile

MEMBERSHIP
S&P 500
SECTOR
Health Care
MARKET CAPITALIZATION

$4 Billion

Mid-Cap
Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, chronic pain, hemophilia, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.

NKTR Earnings

EPS

-0.56

P/E

--

Q2 Earnings for Apr, May & Jun

Thu, Aug 8, 2019

Since Earnings Report

NKTR -25.0%

Q3 Earnings for Jul, Aug & Sep

Wed, Nov 6, 2019

Since Earnings Report

NKTR +16.5%

NKTR Dividend

Dividend Yield

0.00%

Dividend Rate

$0.00

Ex-Dividend Date

--

Dividend Pay Date

--

Dividend Frequency

--

Dividend Payments

--

NKTR Charts

52W Low $15.64
52W High $42.21
All-Time $111.36


NKTR Industry Competitors


BIOTECH & PHARMA
Johnson & Johnson
Merck
Pfizer
Bristol-Myers Squibb
Amgen
Novo Nordisk A/S
AbbVie
Eli Lilly
Sanofi SA (ADR)
Gilead Sciences



Symbol MC DY Price Day YTD
NKTR $4.07 0.00% $21.60 -3.8% -36.9%





Symbol Surfing

How can we make Symbol Surfing better?

info@symbolsurfing.com



    TOP    

©2019 Symbol Surfing All Rights Reserved.

Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Cookies Policy Terms Of Service Privacy Policy